Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCC9 | O60706 | 9/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.47 |
| ▸ | ABCB1 | P08183 | 8/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10266387 | 1.00 | ABCC9 (1.00) | ABCC9CYP3A4ALOX15ABCB1KDM4E | |
| SCHEMBL482523 | 0.85 | ABCC9 (0.73) | ABCC9CYP3A4ALOX15ABCB1KDM4E | |
| SCHEMBL13050144 | 0.82 | ABCC9 (0.70) | ABCC9CYP3A4ALOX15 | |
| SCHEMBL3442662 | 0.81 | ABCC9 (0.78) | ABCC9CYP3A4ALOX15ABCB1KDM4E | |
| SCHEMBL481925 | 0.80 | ABCC9 (0.67) | ABCC9CYP3A4ALOX15ABCB1KDM4E | |
| SCHEMBL7274240 | 0.76 | ABCC9 (0.62) | ABCC9CYP3A4ALOX15ABCB1KDM4E | |
| SCHEMBL482650 | 0.75 | ABCC9 (0.60) | ABCC9CYP3A4ALOX15ABCB1KDM4E | |
| SCHEMBL10265245 | 0.75 | ABCC9 (0.60) | ABCC9CYP3A4ALOX15ABCB1KDM4E | |
| SCHEMBL7330073 | 0.75 | ABCC9 (0.59) | ABCC9CYP3A4ABCB1KDM4E | |
| SCHEMBL7331710 | 0.74 | ABCC9 (0.58) | ABCC9CYP3A4ABCB1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1937669-B9 | NOVEL BENZOPYRAN DERIVATIVES AS POTASSIUM CHANNEL OPENERS | JANSSEN PHARMACEUTICA NV (BE) | 2012-07-18 | — | — | EP | disclosed |
| EP-1937669-B1 | NOVEL BENZOPYRAN DERIVATIVES AS POTASSIUM CHANNEL OPENERS | JANSSEN PHARMACEUTICA NV (BE) | 2012-02-01 | — | — | EP | disclosed |
| US-7838553-B2 | Benzopyran derivatives as potassium channel openers | JANSSEN PHARMACEUTICA NV (BE) | 2010-11-23 | — | — | US | disclosed |
| US-7812183-B2 | Benzopyran derivatives as potassium channel openers | JANSSEN PHARMACEUTICA NV (BE) | 2010-10-12 | — | — | US | disclosed |
| US-20070072832-A1 | NOVEL BENZOPYRAN DERIVATIVES AS POTASSIUM CHANNEL OPENERS | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-03-29 | — | — | US | disclosed |
| US-20070049556-A1 | NOVEL BENZOPYRAN DERIVATIVES AS POTASSIUM CHANNEL OPENERS | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-03-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070049556-A1 | NOVEL BENZOPYRAN DERIVATIVES AS POTASSIUM CHANNEL OPENERS | KCNJ2, KCNN1, KCNN3 | ABCC9 217/4885CYP3A4 370/4885ALOX15 3055/4885 |
| US-20070072832-A1 | NOVEL BENZOPYRAN DERIVATIVES AS POTASSIUM CHANNEL OPENERS | KCNJ2, KCNN1, KCNN3 | ABCC9 217/4885CYP3A4 370/4885ALOX15 3055/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.